Louis Breton is the CEO of ARC Technologies. He is the former CEO of Calimmune, Inc., a gene therapy development company he co-founded in 2006 with Nobel Laureate Dr. David Baltimore, which was acquired by CSL Behring in 2017. Calimmune focused on liberating patients from chronic and, currently incurable, diseases such as HIV and Sickle Cell Disease. Mr. Breton is a husband, father, chaplain, inventor, author, serial entrepreneur and is involved in local charities. With a career in biotechnology spanning more than 25 years, he has helped to craft a new paradigm for the delivery of stem cell gene therapy and regenerative medicine. In 2016, Mr. Breton was recognized by his peers as a PharmaVoice 100 Award recipient. Having built and successfully sold three life science-focused companies, he has been intimately involved in more than 20 different product launches. He has conducted hundreds of licensing deals with academic and government institutions, established international subsidiaries, negotiated with global regulatory bodies, and collaborated with ministries of health of multiple governments. In addition, he has been a board member of 12 biotech and high-tech companies, has presented to the House of Lords on critical gene medicine-based efforts, and was a Business Advisory Council member for a sitting president. Throughout his life, Mr. Breton has worked to bridge the gap between faith and science and is honored to be on the Advisory Board for the Fifth International Vatican Conference.